Navigation Links
Novel experimental agent is highly active in CLL patients, interim study shows
Date:12/11/2011

COLUMBUS, Ohio An interim analysis of a phase Ib/II clinical trial indicates that a novel experimental agent for chronic lymphocytic leukemia (CLL) is highly active and well tolerated in patients who have relapsed and are resistant to other therapy. The agent, called PCI-32765, is the first drug designed to target Bruton's tyrosine kinase, a protein essential for CLL-cell survival and proliferation. CLL is the most common form of leukemia, with about 15,000 new cases annually in the U.S. About 4,400 Americans die of the disease each year.

Study co-leader Dr. John C. Byrd, director of the division of hematology at Ohio State University Comprehensive Cancer Center Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC James) is available to discuss the findings that were presented today (12/13) at the 53rd Annual Meeting of the American Society of Hematology in San Diego.

Study co-leader Dr. Susan O'Brien of The University of Texas M.D. Anderson Cancer Center reported the analysis, which involves 61 patients who have relapsed and whose cancer no longer responds to standard CLL therapy. Of these patients, 27 received a drug dose of 420 milligrams (mg) and 34 received a drug dose of 840 mg.

This study found that 70 percent of patients in the 420-mg group had either a complete or partial remission to treatment after 10 months of follow-up.

"These interim findings are truly exciting because they provide additional evidence that PCI-32765 is a highly active oral therapeutic that produces a high rate of durable remissions the remissions last months on end with acceptable toxicity in relapsed and refractory CLL," Byrd says. "These responses last for many months in part because patients are willing to remain on the drug since the side effects are very tolerable," he notes.

Complete remission means there is no detectable CLL anywhere in the body; partial remission means that the individual's disease volume has decr
'/>"/>

Contact: Darrell E. Ward
Darrell.Ward@osumc.edu
614-293-3737
Ohio State University Medical Center
Source:Eurekalert

Page: 1 2

Related medicine news :

1. NIH grants to Childrens Hospital will advance novel stem cell treatments for blood disorders
2. A novel in vitro model for light-induced wound healing
3. Novel program translates behavioral and social science research into treatments to reduce obesity
4. Reovirus may be a novel approach to prostate cancer treatment
5. Novel stroke treatment passes safety stage of UCI-led clinical trial
6. Novel medical home program for pediatric patients, families cuts ER visits in half
7. MessageSolution First in the Market to Offer All-in-One, Integrated Cloud-Based Archiving for Email, File Systems and SharePoint at Novell BrainShare 2010
8. Novel Parkinson's Treatment Strategy Involves Cell Transplantation
9. Novel Method Eyed for Normalizing Blood Sugar
10. Novel soy germ-based dietary supplement, SE5-OH containing natural S-Equol, examined for safety and influence on hormones in pre- and post-menopausal women
11. Novel nanoparticles prevent radiation damage
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/1/2015)... Turks and Caicos Islands, BWI (PRWEB) May 02, 2015 ... a new website! It is http://www.thevenetiangracebay.com , ... itself, and it incorporates the stunning white and attractive ... to a study of Google, sixty seven percent of ... The study showed that smartphones were used in ...
(Date:5/1/2015)... (PRWEB) May 01, 2015 Jusuru International ... for the successful repositioning of its flagship nutritional supplement, ... brand with a new name, new logo, new packaging, ... Ethos Awards are designed to identify and promote programs ... best. , “DSA congratulates Jusuru International for their ...
(Date:5/1/2015)... 2015 The Workgroup for Electronic ... on the use of health IT to create efficiencies ... resource to the United States Government Accountability Office (GAO) ... cards in Medicare. The report, “ Potential Uses of ... released to the public on Apr. 24, 2015 and ...
(Date:5/1/2015)... It’s raining bills on Capitol Hill with members in both ... for telemedicine. , “Such action is unprecedented in ... said Jonathan Linkous, CEO of the American Telemedicine Association (ATA). ... embrace the use of telecommunications in the delivery of care. ... to improve quality, access, equity and affordability of healthcare.”, ...
(Date:5/1/2015)... KY (PRWEB) May 01, 2015 Ernst ... CEO, Dr. Joshua Rosenthal, Co-Founder & CSO, and Burak ... finalists for the EY Entrepreneur Of The Year® ... Ernst & Young is a global leader in ... to be one of the top audit companies ...
Breaking Medicine News(10 mins):Health News:Turks and Caicos Resort, The Venetian on Grace Bay, Launches New Web Presence 2Health News:Jusuru International Receives 2015 DSA Ethos Award 2Health News:Jusuru International Receives 2015 DSA Ethos Award 3Health News:Jusuru International Receives 2015 DSA Ethos Award 4Health News:Jusuru International Receives 2015 DSA Ethos Award 5Health News:WEDI Contributes to Newly Released U.S. Government Accountability Office (GAO) Study on Potential Use of Electronically Readable Medicare Cards 2Health News:WEDI Contributes to Newly Released U.S. Government Accountability Office (GAO) Study on Potential Use of Electronically Readable Medicare Cards 3Health News:ATA: Congress Floods the Halls with Telemedicine Proposals 2Health News:RowdMap, Inc. Named as a Ernst & Young Entrepreneur Of The Year® 2015 Award Finalist 2
... This release is available in Spanish . ... the same area as the original tumour remains the strongest, ... patients who have been free of disease for a very ... seventh European Breast Cancer Conference (EBCC7). Dr Sven Mieog, ...
... Milan, Italy, 24 March 2010 - Despite the aches and ... a positive outlook, remembering the positive experiences from their past. ... of Elsevier,s Cortex ( http://www.elsevier.com/locate/cortex ), reveals that ... lens is linked to the way in which the brain ...
... ... normal guides on how to assemble a hookah, a free video series demonstrating the ... ... go-to for information, TheHookahMonster.com’s marketing director, Mario Ferazzano, has decided to offer a free ...
... is best way to prevent breast cancer deaths , WEDNESDAY, ... does not appear to increase overall survival from the disease, ... instead be due to controlling risk factors and improved treatments, ... as we hoped years ago," said study author Dr. Karsten ...
... A ... Provo, ... 90 program--a new 90 day risk-free offer in the United States to try Tahitian Noni ... the appropriate amount of product for 90 days, then they can get their full purchase price ...
... ... Turn Back the Clock with a Proven, Personalized, Anti-Aging Program". Dr. Karlis Ullis shares how ... www.AskAnAntiAgingExpert.com . , ... March 24, 2010 -- What do the Today show, Hard Copy, Dateline NBC, and Sally ...
Cached Medicine News:Health News:Recurrence of breast cancer after more than 10 years is an important indicator of survival 2Health News:Recurrence of breast cancer after more than 10 years is an important indicator of survival 3Health News:Older adults remember the good times 2Health News:TheHookahMonster.com Offers Free Shisha Tobacco Education 2Health News:Mammograms May Not Boost Survival, Danish Study Suggests 2Health News:Mammograms May Not Boost Survival, Danish Study Suggests 3Health News:Noni For 90 Offer Made By Tahitian Noni International 2Health News:Free Anti-Aging Teleseminar Teaches People Key Lifestyle Changes To Maximize Longevity 2
(Date:4/30/2015)... April 30, 2015 /PRNewswire/ - Pivotal Therapeutics Inc. ... with a focus on Omega-3 therapies for cardiovascular ... highlights and financial results for the fiscal year ... herein are in Canadian dollars unless otherwise stated. ... significant, with the right strategic partners and additional ...
(Date:4/30/2015)... , April 30, 2015  IRIDEX Corporation (NASDAQ: ... first quarter 2015 financial results after the market closes ... with the release, the Company will host a conference ... Eastern Time on Thursday, May 7, 2015 ... other business developments. Interested parties may access ...
(Date:4/30/2015)... -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX ) announced today ... after the market closes on Thursday, May 7, 2015.  ... held on Thursday, May 7, 2015, at 4:30 p.m. ... participate in the call, please dial 877-303-1298 (for U.S. ... the teleconference will be available for one week and ...
Breaking Medicine Technology:Pivotal Therapeutics Announces 2014 Financial Results 2Pivotal Therapeutics Announces 2014 Financial Results 3Pivotal Therapeutics Announces 2014 Financial Results 4Pivotal Therapeutics Announces 2014 Financial Results 5Pivotal Therapeutics Announces 2014 Financial Results 6IRIDEX Announces First Quarter 2015 Conference Call and Release Date 2Cumberland Pharmaceuticals To Announce First Quarter 2015 Financial Results 2
... FOREST, Ill., March 9, 2011 Hospira, Inc. (NYSE: ... today announced U.S. Food and Drug Administration (FDA) approval of ... and Hospira expects to launch the product later this month. ... a variety of cancers. In 2010, U.S. sales of Taxotere ...
... Tris Pharma, a specialty pharmaceutical company that develops ... US Food and Drug Administration (FDA) has accepted ... the treatment of allergies in kids two years ... Suspension will provide an alternative to the currently ...
Cached Medicine Technology:Hospira Announces U.S. Approval of Generic Docetaxel 2Tris Announces NDA Acceptance of Extended Release Carbinoxamine Oral Suspension for the Treatment of Allergies in Kids Two Years and Older 2
Cushing Flat Drill, only Component Parts and Accessories for HUDSON Cranial Drill. 14 mm...
Hudson brace only. Component parts and accessories for Hudson cranial drill....
Greenberg micro instrument holder is a flexbar arm used to hold micro instruments used repeatedly within retracted fields. Holds instruments with shafts up to 1/8 in diameter....
Length-9 (229 mm) Tapered retractor blades....
Medicine Products: